Eli Lilly said on Monday it will let more patients apply for Eli Lilly retatrutide early access to retatrutide, an unapproved obesity drug. The company said the program applies to a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial.
Six weeks earlier, STAT reported that Lilly had granted a single 79-year-old patient special access to the drug. On Monday, the company said it is actively reviewing requests from health care providers.
STAT request
The announcement followed questions from STAT about expanded access requests from a handful of doctors who had not yet received a reply from the drugmaker. That sequence matters because it shows the company moving from a one-off case to a broader application process after outside pressure for a clearer path.
A Lilly spokesperson said that for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA’s guidance. The company had previously offered little information about the special access program.
Lilly access program
The practical change for patients is narrow but real: instead of relying on a single special-access decision, some people can now apply. The eligibility filter remains tight, though, because the company tied access to specific medical criteria and to patients who cannot get into a trial.
That leaves the program centered on provider requests, not public enrollment. The company has said it is actively reviewing those requests, which means the next step runs through health care providers rather than direct consumer sign-up.
Retatrutide review
For readers trying to figure out whether this opens the door broadly, it does not. Eli Lilly kept the gate narrow, and the source does not say how many additional patients will be approved or when individual decisions will be made.
What changed on Monday is the process: more patients can apply, providers can keep sending requests, and Lilly is now addressing them after giving little information earlier. For patients who qualify, the immediate question is whether a provider will take up the request and whether Lilly will accept it under the medical criteria it described.
